Jardiance® (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

OXFORD, England & INGELHEIM, Germany & INDIANAPOLIS–(BUSINESS WIRE)–The EMPA-KIDNEY trial, evaluating the effect of empagliflozin in adults with chronic kidney disease (CKD), will sto…